Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI (Encorafenib), MEKTOVI (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant...
NEW YORK--(BUSINESS WIRE)--Sep 30, 2019--
NEW YORK--(BUSINESS WIRE)--Sep 30, 2019--